Bank of America Corp DE cut its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 76.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 591,864 shares of the life sciences company's stock after selling 1,946,869 shares during the quarter. Bank of America Corp DE owned 0.77% of Integra LifeSciences worth $13,423,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC lifted its position in shares of Integra LifeSciences by 86.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company's stock worth $30,210,000 after acquiring an additional 618,773 shares during the period. Norges Bank bought a new position in Integra LifeSciences in the fourth quarter worth $8,967,000. Access Investment Management LLC acquired a new stake in Integra LifeSciences during the fourth quarter worth $4,416,000. Jane Street Group LLC increased its holdings in Integra LifeSciences by 269.8% in the 4th quarter. Jane Street Group LLC now owns 224,896 shares of the life sciences company's stock valued at $5,101,000 after buying an additional 164,083 shares during the period. Finally, Cannell & Spears LLC bought a new stake in Integra LifeSciences in the 4th quarter valued at $3,555,000. 84.78% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several analysts have recently weighed in on IART shares. JMP Securities decreased their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Wells Fargo & Company decreased their price objective on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Truist Financial cut their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Finally, JPMorgan Chase & Co. lowered their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Four research analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, Integra LifeSciences presently has a consensus rating of "Hold" and a consensus target price of $18.63.
Get Our Latest Stock Report on IART
Integra LifeSciences Stock Performance
NASDAQ:IART opened at $12.69 on Thursday. The stock has a market capitalization of $986.17 million, a P/E ratio of -140.98, a price-to-earnings-growth ratio of 0.73 and a beta of 1.27. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 1 year low of $11.60 and a 1 year high of $32.66. The firm has a 50 day moving average of $17.45 and a 200-day moving average of $21.54.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The business had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company's revenue for the quarter was up 3.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.55 earnings per share. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.
About Integra LifeSciences
(
Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
